Greenyn Biotechnology Co (ROCO:6846) Beneish M-Score: -3.00 (As of Jun. 27, 2026)


ROCO:6846 Greenyn Biotechnology Co Ltd ROCO:6846
65 GF Score
Price NT$63.70
GF Value NT$66.84
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Greenyn Biotechnology Co Beneish M-Score?

Greenyn Biotechnology Co ROCO:6846 -0.47% 65 Beneish M-Score is -3.00 as of Jun. 27, 2026. GuruFocus rates ROCO:6846 with a GF Score™ of 65/100 and a GF Value™ of NT$66.84 (Fairly Valued). The stock has 6 warning signs investors should review. Among 831 Biotechnology companies, Greenyn Biotechnology Co ranks better than 74.49% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Greenyn Biotechnology Co's Beneish M-Score or its related term are showing as below:

ROCO:6846' s Beneish M-Score Range Over the Past 10 Years
Min: -3   Med: -2.62   Max: -1.88
Current: -3

During the past 7 years, the highest Beneish M-Score of Greenyn Biotechnology Co was -1.88. The lowest was -3.00. And the median was -2.62.


Greenyn Biotechnology Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Greenyn Biotechnology Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Greenyn Biotechnology Co Beneish M-Score Chart

Greenyn Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 0.00 -2.36 -1.88 -2.87 -3.00

Greenyn Biotechnology Co Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.87 -3.09 -3.01 -3.44 -3.00

ROCO:6846 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Greenyn Biotechnology Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Greenyn Biotechnology Co Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Greenyn Biotechnology Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Greenyn Biotechnology Co's Beneish M-Score falls into.


ROCO:6846
65GF Score
Greenyn Biotechnology Co Ltd ROCO:6846
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Greenyn Biotechnology Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Greenyn Biotechnology Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9042+0.528 * 0.9891+0.404 * 0.6815+0.892 * 1.0482+0.115 * 2.0346
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.013+4.679 * -0.006345-0.327 * 2.2954
=-3.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$130.8 Mil.
Revenue was 268.288 + 205.493 + 208.779 + 232.761 = NT$915.3 Mil.
Gross Profit was 129.927 + 100.295 + 94.582 + 115.235 = NT$440.0 Mil.
Total Current Assets was NT$1,484.6 Mil.
Total Assets was NT$2,109.4 Mil.
Property, Plant and Equipment(Net PPE) was NT$575.6 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$35.4 Mil.
Selling, General, & Admin. Expense(SGA) was NT$203.6 Mil.
Total Current Liabilities was NT$217.1 Mil.
Long-Term Debt & Capital Lease Obligation was NT$900.9 Mil.
Net Income was 51.103 + 30.09 + 19.914 + 44.411 = NT$145.5 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0.0 Mil.
Cash Flow from Operations was 49.804 + 31.971 + 40.03 + 37.098 = NT$158.9 Mil.
Total Receivables was NT$138.0 Mil.
Revenue was 246.159 + 209.795 + 191.128 + 226.161 = NT$873.2 Mil.
Gross Profit was 121.541 + 101.046 + 86.228 + 106.413 = NT$415.2 Mil.
Total Current Assets was NT$842.0 Mil.
Total Assets was NT$1,108.7 Mil.
Property, Plant and Equipment(Net PPE) was NT$228.8 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$30.6 Mil.
Selling, General, & Admin. Expense(SGA) was NT$191.8 Mil.
Total Current Liabilities was NT$203.6 Mil.
Long-Term Debt & Capital Lease Obligation was NT$52.4 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(130.788 / 915.321) / (137.994 / 873.243)
=0.142888 / 0.158025
=0.9042

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(415.228 / 873.243) / (440.039 / 915.321)
=0.475501 / 0.480748
=0.9891

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1484.643 + 575.6) / 2109.409) / (1 - (841.978 + 228.771) / 1108.668)
=0.023308 / 0.034202
=0.6815

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=915.321 / 873.243
=1.0482

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(30.612 / (30.612 + 228.771)) / (35.444 / (35.444 + 575.6))
=0.118019 / 0.058006
=2.0346

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(203.608 / 915.321) / (191.753 / 873.243)
=0.222444 / 0.219587
=1.013

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((900.883 + 217.105) / 2109.409) / ((52.384 + 203.599) / 1108.668)
=0.530001 / 0.230892
=2.2954

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(145.518 - 0 - 158.903) / 2109.409
=-0.006345

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Greenyn Biotechnology Co has a M-score of -3.00 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.00 mean?
Greenyn Biotechnology Co (ROCO:6846) has a Beneish M-Score of -3.00 as of Jun. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Greenyn Biotechnology Co and its competitors. According to the industry distribution chart, Greenyn Biotechnology Co ranks #212 out of 831 companies in the Biotechnology industry, placing it in the top 25.5%.
Is Greenyn Biotechnology Co's Beneish M-Score too high?
Greenyn Biotechnology Co's current Beneish M-Score is -3.00. Based on the distribution chart, Greenyn Biotechnology Co ranks #212 out of 831 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Greenyn Biotechnology Co has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Greenyn Biotechnology Co's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Greenyn Biotechnology Co ranks #212 out of 831 companies for Beneish M-Score. This puts Greenyn Biotechnology Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Greenyn Biotechnology Co and its competitors. Greenyn Biotechnology Co's current Beneish M-Score is -3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenyn Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Greenyn Biotechnology Co (ROCO:6846) is currently considered Fairly Valued. The stock's GF Value™ is NT$66.84, compared to a current price of NT$63.70 — trading 4.7% below its estimated fair value. The current Beneish M-Score is -3.00. Greenyn Biotechnology Co's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Greenyn Biotechnology Co (ROCO:6846), the current Beneish M-Score is -3.00 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Greenyn Biotechnology Co (ROCO:6846) Overvalued in 2026?

Based on GuruFocus' analysis, Greenyn Biotechnology Co stock appears to be undervalued. The current stock price of NT$63.70 is trading 4.7% below its estimated GF Value™ of NT$66.84. GuruFocus considers Greenyn Biotechnology Co to be Fairly Valued.

Key valuation signals for ROCO:6846:

  • Beneish M-Score: -3.00
  • GF Value™: NT$66.84 vs. price of NT$63.70 (4.7% below fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the ROCO:6846 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Greenyn Biotechnology Co Business Description

Address No 43 Keya Road, 5th Floor, Daya District, Taichung, TWN
Greenyn Biotechnology Co Ltd is engaged in the business of health food raw materials production and sales of raw materials and production and sales of formula preparation.
65GF Score

Get the complete analysis for ROCO:6846

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$63.70
Price
NT$66.84
GF Value